Chester County News and Community Website
The U.S. Food and Drug Administration recently approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) …
FDA Approves Rebyota for Prevention of CDI Read More
WEST CHESTER, PA — As Jay Leno has taken over headlines for his injuries sustained in a gasoline fire, many have little to no knowledge of the specialized treatment he’s …
Jay Leno: Chester County Hospital Explains Hyperbaric Oxygen Therapy Read More
The U.S. Food and Drug Administration recently approved Xenpozyme (Olipudase alfa) for intravenous infusion in pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease that causes …
FDA Approves Treatment for Rare Genetic Disease Read More
WEST READING, PA — Heather Baum, CRNP, began working in the Surgical Intensive Care Unit (SICU) at Reading Hospital in 2002 as a unit secretary while finishing her undergraduate degree …
Reading Hospital Nurse, a Bariatric Patient, Continues Weight Loss Journey by Joining the Weight Loss and Wellness Center Team Read More WASHINGTON, D.C. — The U.S. Food and Drug Administration says that it recently approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older …
FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test that detects chemical compounds in breath samples associated …
FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples Read More
WEST CHESTER, PA — Brandywine Hall, a 180-bed skilled nursing facility affiliated with Genesis HealthCare, announced that it opened an onsite Dialysis Center with dialysis services last week. In partnership …
Brandywine Hall Announces Opening of New Onsite Dialysis Center Read More
SPRING HOUSE, PA — The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced a Network Meta-Analysis (NMA) comparing first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) to all advanced therapiesa approved for active …
Newly Published Network Meta-Analysis Found TREMFYA Ranked Highest for Overall Level of Skin Clearance, Provided Positive Joint Efficacy Among Active Psoriatic Arthritis Therapies Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) recenlty announced new funding for quality projects to improve patient care and outcomes in lung and thyroid …
NCCN Announces Funding for Lung and Thyroid Cancer Quality Projects, in Collaboration with Lilly Read More
PLYMOUTH MEETING, PA — New research in the January 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined the impact of septic shock on people with hematologic malignancies, finding 67.8% died in fewer …
New Research Raises Awareness of the Dangers of Septic Shock in Blood Cancer Patients Read More